SCHEMBL3131985

SCHEMBL3131985

Cc1ccc(S(=O)(=O)Oc2nc(N)nc3c2CCCc2sccc2-3)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.47
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.34
TP53 P04637 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.33
HRH2 P25021 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
IKBKB O14920 1/20 0.33
P2RY12 Q9H244 1/20 0.33
CYP1A2 P05177 1/20 0.32
HSP90AA1 P07900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877590 0.83 CYP2C19 (0.51) CYP2C19CA12CA2KEAP1NFE2L2
SCHEMBL2166315 0.82 ALDH1A1 (0.49) CYP2C19KEAP1NFE2L2ALDH1A1MAPT
SCHEMBL4878194 0.80 ALDH1A1 (0.47) CYP2C19KEAP1NFE2L2ALDH1A1MAPT
SCHEMBL3135449 0.80 CYP2C19 (0.47) CYP2C19CA12CA2KEAP1NFE2L2
SCHEMBL4876866 0.79 ALDH1A1 (0.46) CYP2C19KEAP1NFE2L2ALDH1A1MAPT
SCHEMBL4875369 0.79 HRH4 (0.48) CYP2C19KEAP1NFE2L2ALDH1A1CYP3A4
SCHEMBL3137466 0.79 CYP2C19 (0.44) CYP2C19CA2KEAP1NFE2L2ALDH1A1
SCHEMBL3133737 0.79 CYP2C19 (0.42) CYP2C19CA2KEAP1NFE2L2ALDH1A1
SCHEMBL3128908 0.77 CYP2C19 (0.47) CYP2C19CA12CA2KEAP1NFE2L2
SCHEMBL4129860 0.76 CYP2C19 (0.61) CYP2C19KEAP1NFE2L2ALDH1A1HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 US disclosed
US-8536166-B2 Inhibitors of Burton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-09-17 US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 US disclosed
US-20100004231-A1 INHIBITORS OF BURTON'S TYROSINE KINASE ROCHE PALO ALTO LLC 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 CYP2C19 318/4885CA12 4805/4885CA2 4740/4885
US-20100004231-A1 INHIBITORS OF BURTON'S TYROSINE KINASE BTK, LCK, LYN CYP2C19 1544/4885CA12 4687/4885CA2 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.